1. NF-κB
  2. NF-κB
  3. SN52

SN52 

Cat. No.: HY-P3229
Handling Instructions

SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

SN52 Chemical Structure

SN52 Chemical Structure

CAS No. : 1071173-56-2

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research[1].

IC50 & Target

IC50: NF-κB2[1]

In Vitro

SN52 (40 μg/ml; 30 mins before DMXAA) inhibits DMXAA-induced nuclear translocation of RelB in BMDCs[1].
SN52 does not change the activation of canonical NF-κB signaling. The nuclear translocation of RelB is increased in DCs isolated from irradiated tumors, and SN52 abolishes this activation in activated DC cells[1].
SN52 (40 μg/mL; 30 mins before co-cultured with irradiated or non-irradiated MC38 cells) inhibits the non-canonical NF-κB and increases Ifn-b expression in BMDCs stimulated with irradiated tumor cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SN52 (intrathecal injection; 40 μg/ml; day-1, day 1 and day 3 of 20Gy radiation of radiation) combines with IR enhances anti-tumor immune functions of both DCs and CD8+ T cells and subsequently reduced tumor burden more effectively compared with IR alone[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Tumor mice model[1]
Dosage: 40 μg
Administration: Intrathecal injection; 40 μg; day-1, day 1 and day 3 of 20Gy radiation of radiation
Result: Reduced tumor burden than IR group alone.
Induced non-canonical NF-κB inhibition and potentiates the anti-tumor effect of IR.
Molecular Weight

2749.43

Formula

C₁₂₈H₂₃₀N₃₈O₂₈

CAS No.
Sequence Shortening

AAVALLPAVLLALLAPVQRKRRKALP

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

SN52SN 52SN-52NF-κBNuclear factor-κBNuclear factor-kappaBSN50NF-κB2p52-RelBCANCER prostateheterodimerradiosensitizationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SN52
Cat. No.:
HY-P3229
Quantity:
MCE Japan Authorized Agent: